/
Respiratory
LAM
12
Pipeline Programs↗
6
Active Trials↗
28
Companies Involved↗
LAM is an emerging landscape with 12 programs across 28 companies. The most active players are Gan and Lee Pharmaceuticals, USA. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 26
Phase 31
Approved
No programs
Analysis
Modality Breakdown
91%
Small molecule
10 of 11 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 12 pipeline programs.
Analysis
Trial Status
146
clinical trials
Completed117 · 80%
Unknown status12 · 8%
Withdrawn6 · 4%
Terminated5 · 3%
Recruiting5 · 3%
Active, not recruiting1 · 1%
Clinical Trials
Trial Activity
146 trials
Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fasting Condition
Completed·—·Phase 1·NCT01131949·26 enrolled
Bioequivalence Study of Lamotrigine Extended-Release Tablets 50 mg Under Fasting Condition
Completed·—·Phase 1·NCT01888731·62 enrolled
Lamotrigine Extended-Release Tablets 50 mg Under Fed Condition
Completed·—·Phase 1·NCT01888757·62 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)